A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

President Trump has vowed to impose tariffs on China, Mexico, and Canada. They could make common medicines less affordable.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

AstraZeneca PLC AZN shares inched down 0.11% to £110.40 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.04% to 8,545.13.

Bearish flow noted in AstraZeneca (AZN) with 1,547 puts trading, or 1.9x expected. Most active are 2/14 weekly 68 puts and Feb-25 70 puts, with ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...